(Q36167378)

12 August 2017

4 references

5 November 2020

22 October 2022

25 October 2022

26 October 2022

Rituximab-based treatment, HCV replication, and hepatic flares (English)

1 reference

tumor of hematopoietic and lymphoid tissues

12 August 2017

1 reference

5 November 2020

1 reference

3 November 2019

4 references

22 July 2020

22 October 2022

25 October 2022

26 October 2022

murine-derived monoclonal antibodies

1 reference

PubMed

1 August 2020

viral genome replication

1 reference

PubMed

antineoplastic combined chemotherapy protocols

5 November 2020

1 reference

23 September 2020

Mariantonietta Pisaturo

Mariantonietta Pisaturo

2

0 references

Caterina Sagnelli

Caterina Sagnelli

3

0 references

Nicola Coppola

Nicola Coppola

4

0 references

Evangelista Sagnelli

Evangelista Sagnelli

1

0 references

language of work or name

1 reference

5 August 2012

18 references

Clinical and Developmental Immunology

12 August 2017

23 March 2019

21 March 2019

3 April 2019

25 June 2019

27 September 2019

3 November 2019

27 November 2019

13 December 2019

1 July 2020

22 July 2020

1 August 2020

15 September 2020

23 September 2020

5 November 2020

22 October 2022

25 October 2022

26 October 2022

18 references

12 August 2017

23 March 2019

21 March 2019

3 April 2019

25 June 2019

27 September 2019

3 November 2019

27 November 2019

13 December 2019

1 July 2020

22 July 2020

1 August 2020

15 September 2020

23 September 2020

5 November 2020

22 October 2022

25 October 2022

26 October 2022

2012

1 reference

12 August 2017

945950

1 reference

Creative Commons Attribution 3.0 Unported

12 August 2017

17 references

23 March 2019

21 March 2019

3 April 2019

25 June 2019

27 September 2019

3 November 2019

27 November 2019

13 December 2019

1 July 2020

22 July 2020

1 August 2020

15 September 2020

23 September 2020

5 November 2020

22 October 2022

25 October 2022

on focus list of Wikimedia project

26 October 2022

copyright status

copyrighted

0 references

ScienceSource

0 references

cites work

Hepatitis C reactivation in patients who have diffuse large B-cell lymphoma treated with rituximab: a case report and review of literature

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420110

Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420110

Reactivation of hepatitis B with reappearance of hepatitis B surface antigen after chemotherapy and immunosuppression.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420110

Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420110

Changes in hepatitis C virus antibody titer and viral RNA load in non-Hodgkin’s lymphoma patients after rituximab chemotherapy

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420110

Hepatitis C virus lymphotropism: lessons from a decade of studies.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420110

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420110

Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand?

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420110

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420110

Prophylaxis and treatment of hepatitis B in immunocompromised patients

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420110

Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: analysis of 156 patients from northern Italy

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420110

Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420110

Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420110

The spectrum of extrahepatic manifestations in hepatitis C virus infection

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420110

Anticardiolipin antibodies in chronic hepatitis C: implication of hepatitis C virus as the cause of the antiphospholipid syndrome.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420110

Extrahepatic immunologic manifestations in chronic hepatitis C and hepatitis C virus serotypes

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420110

Hepatitis C: a multifaceted disease. Review of extrahepatic manifestations

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420110

High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420110

Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420110

Characterization of a human B lymphocyte-specific antigen.

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420110

A role for hepatitis C virus infection in type II cryoglobulinemia

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420110

Lymphocytic sialadenitis of Sjögren's syndrome associated with chronic hepatitis C virus liver disease

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420110

Infection of peripheral mononuclear blood cells by hepatitis C virus

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420110

Hepatitis C virus infection in patients with essential mixed cryoglobulinemia

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420110

Hepatitis C virus infection in patients with non-Hodgkin's lymphoma

2 July 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F945950

Hepatitis C virus infection in patients with B-cell non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F945950

Cryoglobulinemia with vasculitis associated with hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F945950

CHOP plus rituximab--balancing facts and opinion

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F945950

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F945950

Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F945950

A revisit of prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin's lymphoma: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F945950

Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F945950

Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F945950

Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F945950

Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F945950

Accelerated hepatitis C virus replication with rituximab treatment in a non-Hodgkin's lymphoma patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F945950

Hepatic toxicity and prognosis in hepatitis C virus-infected patients with diffuse large B-cell lymphoma treated with rituximab-containing chemotherapy regimens: a Japanese multicenter analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F945950

HCV genotype 2 as a risk factor for reactivation in patients with B-cell lymphoma undergoing rituximab combination chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F945950

HCV-positive status and hepatitis flares in patients with B-cell non-Hodgkin's lymphoma treated with rituximab-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F945950

Increased hepatitis C viral load and reactivation of liver disease in HCV RNA-positive patients with onco-haematological disease undergoing chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F945950

Rituximab-induced hepatitis C virus reactivation after spontaneous remission in diffuse large B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F945950

Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F945950

Glucocorticosteroids increase cell entry by hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F945950

Absence of occult hepatitis C virus infection in patients under immunosupressive therapy for oncohematological diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F945950

Hepatitis C virus and alanine aminotransferase kinetics following B-lymphocyte depletion with rituximab: evidence for a significant role of humoral immunity in the control of viremia in chronic HCV liver disease

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420110

Prevalence of hepatitis C virus infection in patients with lymphoproliferative disorders

23 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3420110

Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas

23 September 2018

1 reference

https://api.crossref.org/works/10.1155%2F2012%2F945950

Reactivation of overt and occult hepatitis B infection in various immunosuppressive settings

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22919406

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1155/2012/945950

1 reference

12 August 2017

1 reference

PMC publication ID

3420110

12 August 2017

PubMed publication ID

22919406

1 reference

PMC publication ID

3420110